Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sensus Gains China Approval of Radiation Device for Keloids

publication date: Jul 26, 2017
The CFDA approved a superficial radiation therapy device made by Sensus Healthcare of the US to treat and prevent keloids. Keloids are raised scars formed from benign fibrous tissue. Sensus' SRT-100™ device is based on a proprietary low-energy x-ray technology. Chindex Medical, a medical device distributor owned by Fosun Pharma, has been distributing the SRT-100 device in China for non-melanoma skin cancers since 2014. It plans to emphasize use of the device to prevent keloids associated with Cesarean sections. More details....

Stock Symbols: (NSDQ: SRTS) (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital